Conference Coverage

VIDEO: Pembrolizumab may herald new hope in advanced melanoma


 

AT THE ASCO ANNUAL MEETING 2014

CHICAGO – Results from a phase I study of investigational PD-1 antibody pembrolizumab may point the way toward higher treatment response rates and less toxicity in patients with advanced metastatic melanoma.

Of 411 patients who took pembrolizumab, 1-year overall survival was 69%, and 88% of patients who had a treatment response continued to have a response at 1 year, reported Dr. Antoni Ribas, professor of medicine at the University of California, Los Angeles.

In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. Ribas discussed the study results and explained how PD-1 antibodies help the immune system recognize and mount a more potent T-cell–mediated defense against melanoma.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

AUDIO: Chemotherapy toxicities masquerade as skin disease
MDedge Hematology and Oncology
Single-fraction radiation therapy showed promise in metastatic Merkel cell carcinoma
MDedge Hematology and Oncology
Infrared detector distinguished malignant and benign skin lesions
MDedge Hematology and Oncology
Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Nonmelanoma skin cancer linked to increased fracture risk in postmenopausal women
MDedge Hematology and Oncology
Drugs approved in 2013
MDedge Hematology and Oncology
Consumer Reports: Sunscreen SPF claims largely inaccurate
MDedge Hematology and Oncology
ASCO 2014: Dr. Jeffrey A. Sosman gives his top picks in melanoma research
MDedge Hematology and Oncology
High rate of durable responses to pembrolizumab in metastatic melanoma
MDedge Hematology and Oncology
‘Unprecedented’ overall survival of metastatic melanoma
MDedge Hematology and Oncology